Evaluation Platform for Bispecific Antibodies
WuXi AppTec offers a full range of services to characterize bispecific antibodies and bispecific T cell engagers (BiTEs). Our comprehensive...
Continue Reading
WuXi AppTec offers a full range of services to characterize bispecific antibodies and bispecific T cell engagers (BiTEs). Our comprehensive...
Continue Reading
Lysosomal storage disorders (LSDs) are rare genetic conditions that cause a buildup of toxic materials in the cells of various...
Continue Reading
To accelerate screening and lead optimization efforts involving immune cell differentiation, WuXi AppTec offers a comprehensive CD34+ hematopoietic stem cell...
Continue Reading
We have established an enzalutamide-resistant (LNCaP AR-F877L mutation) KI prostate cancer model to support the development of next-generation therapeutics. An...
Continue Reading
We offer an extensive panel of inflammatory bowel disease models in mice and rats, including genetically modified, chemically induced, and...
Continue Reading
Drug Discovery Chemistry Conference 2023 WuXi AppTec has developed technologies to facilitate RNA small molecule screening, an exciting frontier in...
Continue Reading
Drug Discovery Chemistry Conference Powerful biophysical and structural biology tools enable the study of large numbers of covalent fragments and...
Continue Reading
Drug Discovery Chemistry Conference 2023 DNA-Encoded library (DEL) screening is now commonly used in the pharmaceutical industry to find novel...
Continue Reading
Our comprehensive panel of orthotopic and metastasis syngeneic models includes: 17 orthotopic/disseminated models covering 10 cancer types; Organ-based orthotopic models...
Continue Reading